From a safety standpoint, retatrutide's known adverse effect profile from phase II trials includes: Nausea, vomiting, and diarrhoea (gastrointestinal effects common to GLP-1 receptor agonists) Reduced appetite and potential nutritional deficiencies with prolonged use Elevated heart rate observed in some trial participants Pancreatitis and gallbladder disease , which are recognised class cautions for GLP-1based therapies and should be considered in the context of retatrutide, although retatrutide-specific data remain limited Thyroid C-cell changes , observed in rodent studies with GLP-1 receptor agonists
The competitive map is widening, too, as the Novo Nordisk and Eli Lilly duopoly meets oral small molecules, monthly dosing, Eli Lillys retatrutide, a triple hormone receptor agonist, has demonstrated an average weight loss of 28.3% over 80 weeks on the highest dose in Phase 3 trials
It is an intriguing source of bioactive components, including cynaropicrin, phenolics, minerals, inulin, fiber, and sesquiterpene lactones, making it a functional food with great nutritional value
We monitor all patients carefully
A tiny sensor is inserted, using an applicator, into a fatty part of the body such as the abdominal or upper buttocks area
